TCRX
TScan Therapeutics, Inc.
Latest Form 4:Purchase$72KbyLynx1 Capital Management LP (10% Owner) · filed Dec 23, 2025
TScan Therapeutics, Inc. (TCRX) has 1 SEC Form 4 filing (3 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Dec 23, 2025.
The most active filer is 10% Owner Lynx1 Capital Management LP with 3 filings. Insiders have net bought $146K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Gavin MacBeath
- Employees:139
- HQ:Waltham, MA, US
- IPO:2021-07-16
Insider Buying
$146K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Lynx1 Capital Management LPFirst filing | 10% Owner | Purchase | 80,069 | $72K | Dec 23 | SEC ↗ |
Lynx1 Capital Management LPFirst filing | 10% Owner | Purchase | 75,500 | $68K | Dec 23 | SEC ↗ |
Lynx1 Capital Management LPFirst filing | 10% Owner | Purchase | 6,232 | $6K | Dec 23 | SEC ↗ |
Related companies
TScan Therapeutics, Inc. is in the Healthcare sector.